Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4203477 | 0.90 | USP2 (0.35) | KMT2AHTTUSP2DNM1NAMPT | |
| SCHEMBL30753853 | 0.84 | KMT2A (0.45) | KMT2AHTTDNM1TDP1EPHX2 | |
| SCHEMBL27748816 | 0.82 | EPHX2 (0.44) | KMT2AHTTDNM1TDP1EPHX2 | |
| SCHEMBL5572067 | 0.80 | KMT2A (0.54) | KMT2AHTTTDP1CYP2C19NAMPT | |
| SCHEMBL13160340 | 0.79 | ALDH1A1 (0.49) | KMT2ACYP2C19 | |
| SCHEMBL11032609 | 0.79 | HTT (0.61) | KMT2AHTTSMN1; SMN2 | |
| SCHEMBL10673469 | 0.79 | KMT2A (0.46) | KMT2AHTTDNM1TDP1MAPK1 | |
| SCHEMBL4555741 | 0.76 | HTT (0.57) | KMT2AHTTTDP1NAMPTMAPK1 | |
| SCHEMBL5238596 | 0.76 | KMT2A (0.72) | KMT2AHTTTDP1SMN1; SMN2MAPK1 | |
| SCHEMBL2603259 | 0.76 | KMT2A (0.42) | KMT2AHTTDNM1TDP1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | CCNI, MKI67, CDK2 | KMT2A 1807/4885HTT 4182/4885USP2 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.